The SNMMI and EANM practice guideline for renal scintigraphy in adults
- 455 Downloads
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) is an international scientific and professional organization founded in 1954 to promote the science, technology, and practical application of nuclear medicine. The European Association of Nuclear Medicine (EANM) is a professional nonprofit medical association that facilitates communication worldwide between individuals pursuing clinical and research excellence in nuclear medicine. The EANM was founded in 1985. SNMMI and EANM members are physicians, technologists, and scientists specializing in the research and practice of nuclear medicine.
The SNMMI and EANM will periodically define new guidelines for nuclear medicine practice to help advance the science of nuclear medicine and to improve the quality of service to patients throughout the world. Existing practice guidelines will be reviewed for revision or renewal, as appropriate, on their fifth anniversary, or sooner, if indicated.
Each practice guideline, representing a policy statement by the SNMMI/EANM, has undergone a thorough consensus process in which it has been subjected to extensive review. The SNMMI and EANM recognize that the safe and effective use of diagnostic nuclear medicine imaging requires specific training, skills, and techniques, as described in each document. Reproduction or modification of the published practice guideline by entities not providing these services is not authorized.
KeywordsRenal dynamic scan Renal static scan Adults EANM SNMMI Guideline
The authors acknowledge the EANM board, the EANM national delegates, the of the EANM Committees, and members of the SNMMI Committee on Guidelines for their contributions to this manuscript.
The SNMMI Procedure Standards Committee consists of the following individuals:
Dominique Delbeke, MD, PhD, FSNMMI (Chair; Vanderbilt University Medical Center, Nashville, TN); Kevin J. Donohoe, MD (Beth Israel Deaconess Medical Center, Boston, MA); Helena Balon, MD (Beaumont Health System, Royal Oak, MI); Twyla Bartel, DO, MBA, FACNM (Global Advanced Imaging, PLLC, Little Rock, AR); Vasken Dilsizian, MD (University of Maryland Medical Center, Baltimore, MD); James R. Galt, PhD (Emory University Hospital, Atlanta, GA); Jay A. Harolds, MD (Advanced Radiology Services, PC, Grand Rapids, MI); J. Anthony Parker, MD, PhD (Beth Israel Deaconess Medical Center, Boston, MA); Lynne T. Roy, MBA, CNMT, FSNMMI-TS (Cedars/Sinai Medical Center, Los Angeles, CA); Heiko Schoder, MD (Memorial Sloan-Kettering Cancer Center, New York, NY); Barry L. Shulkin, MD, MBA (St. Jude Children’s Research Hospital, Memphis, TN); Michael G. Stabin, PhD (Vanderbilt University, Nashville, TN); Mark Tulchinsky, MD, FACNM, CCD (Milton S. Hershey Medical Center, Hershey, PA); Bennett Greenspan, MD, FACNM, FACR (Medical College of Georgia, Augusta, GA); Darko Pucar, MD, PhD (Yale New Haven Hospital, New Haven, CT); David Brandon, MD (Emory University, Atlanta, GA); Erica Cohen, DO, MPH, CCD, FACNM (Edward Hines VA, Hines, IL); Laurel Campbell, BS, CNMT, RT(N)(CT) (Brigham and Women’s Hospital, Boston, MA); Perry Gerard, MD (Woodmere, NY); Pradeep Bhambhvani, MD (The University of Alabama at Birmingham, Birmingham, AL); Aaron Jessop, MD, MBA (Vanderbilt University Medical Center, Nashville, TN); Alan Packard, PhD (Boston Children’s Hospital/Harvard Medical School, Boston, MA); Amir Khandani, MD (University of North Carolina, Chapel Hill, NC).
The EANM Board consists of the following individuals:
Jolanta Kunikowska, MD, PhD (Nuclear Medicine Department, Medical University of Warsaw, Poland); Francesco Giammarile, MD, PhD (Nuclear Medicine and Diagnostic Imaging Section, International Atomic Energy Agency, Vienna, Austria); Willem J.G. Oyen, MD, PhD (The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Department of Nuclear Medicine, London, UK); Jan Pruim, MD, PhD (Medical Imaging Center, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands); Roberto Delgado Bolton, MD, PhD (University Hospital San Pedro, Logroño, La Rioja, Spain); Kristoff Muylle, MD (UniversitairZiekenhuisBrussel-VUB, Brussels, Belgium).
Compliance with ethical standards
These procedures were approved by the SNMMI and EANM Boards.
Conflict of interest
All authors declare that they have no conflict of interest.
Ethical approval: This article does not contain any studies with human participants or animals performed by any of the authors.
- 2.Boubaker A, Prior JO, Meuwly JY, Bischof-Delaloye A. Radionuclide investigations of the urinary tract in the era of multimodality imaging. J Nucl Med. 2006;47:1819–36.Google Scholar
- 5.Rado JP, Bano C, Tako J. Radioisotope renography during furosemide (Lasix) diuresis. Nucl Med Commun. 1968;7:212–21.Google Scholar
- 22.Bubeck B, Brandau W, Eisenhurt M, et al. The tubular extraction rate (TER) of Tc-99m MAG3: a new quantitative parameter for renal parameter of renal function. Nucl Compact. 1987;18:260–7.Google Scholar
- 30.ICRP publication 80. Absorbed doses. Radiation dose to patients from radiopharmaceuticals. Addendum 2 to ICRP publication. Oxford: Pergamon Press; 1998.Google Scholar
- 39.Rutland MD. Glomerular filtration rate using 99mTc DTPA and a gamma camera. Eur J Nucl Med. 1983;4:425–33.Google Scholar
- 42.Fine EJ, Blaufox MD, On Behalf of the Albert Einstein College of Medicine/Cornell University Medical Center Collaborative Hypertension Group. The Einstein/Cornell collaborative protocol to assess efficacy and methodology in captopril scintirenography. Am J Hypertens. 1991;4:716S–20S.CrossRefGoogle Scholar
- 43.Prigent A, Cosgriff P, Gates GF, et al. Consensus report on quality control of quantitative measurements of renal function obtained from the renogram: international consensus committee from the scientific Committee of Radionuclides in Nephrourology. Semin Nucl Med. 1999;29(2):146–59.CrossRefGoogle Scholar